Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENO1 | P06733 | 4/20 | 0.82 |
| ▸ | THRB | P10828 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 6/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22266129 | 0.91 | ENO1 (0.81) | ENO1CHRM3 | |
| SCHEMBL22275838 | 0.90 | ENO1 (1.00) | ENO1MEN1KMT2A | |
| SCHEMBL25544138 | 0.89 | ENO1 (0.84) | ENO1KMT2AOPRK1 | |
| SCHEMBL25544139 | 0.86 | ENO1 (0.74) | ENO1CHRM3 | |
| SCHEMBL22266134 | 0.86 | ENO1 (0.76) | ENO1MEN1KMT2ACHRM3MAPT | |
| SCHEMBL22265938 | 0.85 | ENO1 (0.83) | ENO1MEN1KMT2ACHRM3 | |
| SCHEMBL25544140 | 0.85 | ENO1 (0.69) | ENO1CHRM3 | |
| SCHEMBL22266063 | 0.84 | ENO1 (0.76) | ENO1MEN1KMT2ACHRM3 | |
| SCHEMBL25544397 | 0.83 | ENO1 (0.68) | ENO1MEN1KMT2ACHRM3 | |
| SCHEMBL23884968 | 0.82 | ENO1 (0.77) | ENO1MEN1KMT2ACHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230167142-A1 | METHODS FOR THE MONO-AMIDATION OF PHOSPHATES AND PHOSPHONATES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2023-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230167142-A1 | METHODS FOR THE MONO-AMIDATION OF PHOSPHATES AND PHOSPHONATES | PHPT1, PPIP5K2, PNP | ENO1 867/4885THRB 3637/4885MEN1 561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.